A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.
Public ClinicalTrials.gov record NCT07470853. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1 First-in-Human Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
HWK-016-101 is a multicenter, open-label, first-in-human (FIH) Phase 1 study evaluating HWK-016, a targeted antibody-drug conjugate (ADC) in adult participants with advanced or metastatic solid tumors. The study employs a dose escalation and dose expansion design without a control group. The study consists of 2 parts (Part A: monotherapy and Part B: combination therapy with bevacizumab); each part has 2 phases, Phase 1a (dose escalation) and Phase 1b (dose expansion). Enrollment to Part A (Phase 1a and Phase 1b) will include ovarian and endometrial cancers. Enrollment to Part B (Phase 1a and Phase 1b) will include ovarian cancer only. A subsequent protocol amendment may evaluate additional tumor types.
Study identification
- NCT ID
- NCT07470853
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 265 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 14, 2026
- Primary completion
- Jan 31, 2028
- Completion
- Jan 31, 2028
- Last update posted
- Aug 17, 2026
2026 – 2028
United States locations
- U.S. sites
- 12
- U.S. states
- 11
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Arkansas - Winthrop P. Rockefeller Cancer Institute | Little Rock | Arkansas | 72205 | Recruiting |
| START - Los Angeles | Los Angeles | California | 90025 | Recruiting |
| SCRI - Florida Cancer Specialists | Sarasota | Florida | 34232 | Recruiting |
| St. Francis Medical Center (OSF Healthcare) | Peoria | Illinois | 61637 | Recruiting |
| Karmanos Cancer Center | Detroit | Michigan | 48201 | Not yet recruiting |
| Start - Ny | Long Island City | New York | 11042 | Recruiting |
| Memorial Sloan Kettering Cancer Center | New York | New York | 07920 | Not yet recruiting |
| Atrium Health - Wake Forest | Charlotte | North Carolina | 282204 | Not yet recruiting |
| Ohio State University Wexner Medical Center | Columbus | Ohio | 43210 | Recruiting |
| SCRI - Sydney Kimmel Cancer Center - Jefferson Health | Philadelphia | Pennsylvania | 19107 | Recruiting |
| SCRI - Mary Crowley Cancer Research | Dallas | Texas | 75230 | Recruiting |
| START Mountain | Salt Lake City | Utah | 84119 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07470853, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 17, 2026 · Synced Sep 13, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07470853 live on ClinicalTrials.gov.